Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Etrasimod in Ulcerative Colitis
jRCT2071200081Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Long-term safety profile of etrasimod. Started Jan 2021; status: active, not recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071200081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200081.